Management of patients with advanced non-small cell lung cancer: current and emerging options.

摘要: Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau been reached traditional chemotherapy, efforts are now being directed at developing molecularly targeted agents. To date, three such agents have found to improve survival NSCLC. Erlotinib, a small-molecule inhibitor epidermal growth factor receptor, was approved by US FDA 2004 as second- or third-line treatment Bevacizumab, an antibody vascular endothelial factor, key mediator angiogenesis, received approval 2006, after randomized trial reported median 1 year when bevacizumab added first-line chemotherapy. More recently, cetuximab, outcome is anticipated. Several additional currently evaluated trials, encouraging results from early studies. These other studies prospectively investigating predictive clinical molecular characteristics, ultimate goal individualizing